吡柔比星热灌注联合全身化疗治疗晚期膀胱癌的疗效与安全性评价  

Efficacy and safety of pirarubicin hot perfusion combined with systemic chemotherapy in the treatment of advanced bladder cancer

作　　者：罗松涛[1] 王应洪[1] 廖大忠[1] 王明杰[1] 李绪鲲[1] 唐伟[1] 刘星[1] 柯井卫[1] 唐义权[1] 

机构地区：[1]泸州医学院附属中医医院外五科,四川泸州646000

出　　处：《中国临床药理学杂志》2015年第3期184-186,共3页The Chinese Journal of Clinical Pharmacology

基　　金：泸州医学院附属中医医院联合科研基金资助项目(2013-S-47)

摘　　要：目的评价吡柔比星热灌注联合全身化疗对晚期膀胱癌患者的临床疗效及不良反应。方法收治晚期膀胱癌患者47例,单纯吉西他滨+顺铂(GP)方案全身化疗者24例(对照组),GP联合吡柔比星热灌注化疗者23例(试验组)。对照组:第1,8天静脉滴注吉西他滨1000 mg·m-2;第2,3,4天静脉滴注顺铂30 mg·m-2,28 d为1个周期,化疗4个周期;治疗组:在对照组的基础上膀胱内灌注吡柔比星20 mg,每周1次,共8周。评价2组患者的客观疗效及不良反应。结果化疗4个周期后,治疗组客观有效率为78.3%,对照组为41.7%,治疗组显著高于对照组(P<0.05)。治疗组和对照组组患者各项药品不良反应发生率分别为17.4%和20.8%,差异无统计学意义(P>0.05)。结论吡柔比星热灌注联合GP方案治疗可显著提高晚期膀胱癌患者的临床疗效且不增加相关不良反应。Objective To evaluate the effects and safety of pirarubicin hot perfusion chemotherapy combined with gemcitabine and cisplation on advanced bladder cancer. Methods Forty- seven patients with advanced bladder cancer were divided into control group（ 24 cases） and treatment group（ 23 cases）. Patients in control group were treated with gemcitabine l 000 mg · m^-2 on day 1 and day 8 and cisplation 30mg·m^-2 on day 2,3 and 4 through intravenous injection with 4 cycles of chemotherapy（ 28 days as a cycle）. Patients in treatment group were treated with pirarubicin 20 mg through bladder infusion on the basis of the treatment of control group,once a week for 8 weeks. The data of clinical efficacy and adverse reactions were evaluated between the two groups. Results After 4 cycles chemotherapy,the objective response rate of treatment group（ 78. 3%） was much higher than that in control group（ 41. 7%）（ P〈0. 05）. The occurrence rate of adverse drug reactions in treatment group and control group were 17. 4% and 20. 8%,and there was no statistical differences between the two groups（ P〉0. 05）.Conclusion Pirarubicin hot perfusion chemotherapy combined with gemcitabine and cisplation can significantly improve the efficacy of advanced bladder cancer without increasing the adverse reactions.

关 键 词：膀胱癌 吡柔比星 热灌注化疗 临床疗效 安全性 

分 类 号：R730.53[医药卫生—肿瘤] R737.14[医药卫生—临床医学]